Pancreatic Exocrine Insufficiency
16
1
2
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 16 trials
100.0%
+13.5% vs benchmark
38%
6 trials in Phase 3/4
57%
4 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (16)
Pancreatic Enzyme Replacement in Acute Necrotizing Pancreatitis
IPEX Study: Pancreatic Exocrine Insufficiency as a Functional Marker of Disease Progression in Patients With IPMN
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
Investigation on the Current Situation and Risk Factors Analysis of Exocrine Insufficiency in Chronic Pancreatitis
Medication Adherence to Phone-supervised Pancreatic Enzyme Replacement Therapy
The Effect of PERT on Patients Undergoing Pancreaticoduodenectomy
Establishment and Clinical Application of Pancreatic Endocrine and Exocrine Function Tests
The Development of a Metabolomic Test to Diagnose and Quantify Pancreatic Exocrine Insufficiency (The DETECTION Study)
PE-1 in the Diagnosis of Pancreatic Exocrine Insufficiency
Screening for Pancreatic Exocrine Insufficieny in Metabolic Associated Fatty Liver Disease Patients
Impact of Pancreatic Endoscopic Drainage on Exocrine Pancreatic Function in Unresectable Pancreatic Cancer
Intestinal Microbiota Composition in Patients With Chronic Pancreatitis and Pancreatic Exocrine Insufficiency
Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency
A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy
Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)